Raymond James & Associates boosted its stake in shares of Chemed Co. (NYSE:CHE – Free Report) by 0.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 72,310 shares of the company’s stock after acquiring an additional 224 shares during the quarter. Raymond James & Associates owned approximately 0.48% of Chemed worth $39,234,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in CHE. Norges Bank bought a new stake in Chemed during the 4th quarter worth about $92,359,000. TD Asset Management Inc grew its holdings in Chemed by 164.3% during the 4th quarter. TD Asset Management Inc now owns 205,777 shares of the company’s stock worth $120,328,000 after acquiring an additional 127,934 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Chemed by 121.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 203,096 shares of the company’s stock worth $118,760,000 after acquiring an additional 111,399 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Chemed during the 4th quarter worth about $430,970,000. Finally, Epoch Investment Partners Inc. boosted its stake in shares of Chemed by 85.2% in the 4th quarter. Epoch Investment Partners Inc. now owns 152,162 shares of the company’s stock valued at $88,977,000 after purchasing an additional 70,001 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.
Chemed Trading Up 0.2 %
Shares of NYSE CHE opened at $577.57 on Tuesday. The firm has a market capitalization of $8.74 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 2.40 and a beta of 0.43. Chemed Co. has a 1 year low of $492.84 and a 1 year high of $654.62. The firm’s 50-day moving average is $550.69 and its 200-day moving average is $581.10.
Chemed Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, August 30th. Investors of record on Monday, August 12th will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.35%. This is an increase from Chemed’s previous quarterly dividend of $0.40. The ex-dividend date is Monday, August 12th. Chemed’s dividend payout ratio (DPR) is currently 10.76%.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on CHE. StockNews.com raised shares of Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Royal Bank of Canada reduced their target price on shares of Chemed from $712.00 to $697.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 21st.
Get Our Latest Stock Analysis on CHE
Insider Activity at Chemed
In related news, CEO Kevin J. Mcnamara sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $544.17, for a total value of $816,255.00. Following the sale, the chief executive officer now directly owns 107,049 shares in the company, valued at approximately $58,252,854.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Chemed news, EVP Nicholas Michael Westfall sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $561.58, for a total transaction of $1,123,160.00. Following the sale, the executive vice president now directly owns 5,990 shares in the company, valued at approximately $3,363,864.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin J. Mcnamara sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $544.17, for a total transaction of $816,255.00. Following the sale, the chief executive officer now owns 107,049 shares in the company, valued at $58,252,854.33. The disclosure for this sale can be found here. Insiders have sold 5,784 shares of company stock worth $3,232,313 in the last ninety days. Company insiders own 3.32% of the company’s stock.
Chemed Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- Canadian Penny Stocks: Can They Make You Rich?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Breakout Stocks: What They Are and How to Identify Them
- 2 Option Strategies to Maximize Profits in a Bear Market
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Lululemon Stock Gears Up for a Massive Comeback Rally
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.